Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmatory Study of Lonasen Tape (DSP-5423P) in Schizophrenia
NCT02287584Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of blonanserin in schizophrenia (3 arms), sponsored by Sumitomo Pharma. Primary endpoint: Change in Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Dec 2014; status: completed.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02287584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287584.